1-6 of 6
Brian Fox
Close
Sort by
Journal Articles

Molecular, Epigenetic, and Immune Landscape of TP53- mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)

Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan G. Thompson, Daniel Lopes de Menezes, Shelonitda Rose, Isaac W. Boss, Stephanie Halene, Torsten Haferlach, Brian Fox, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 6247–6249.
https://doi.org/10.1182/blood-2022-156460
Published: 2022
Journal Articles

Impact of Allelic State on Overall Survival in TP53- mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)

Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan G. Thompson, Daniel Lopes de Menezes, Shelonitda Rose, Isaac W. Boss, Stephanie Halene, Torsten Haferlach, Brian Fox, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 8910–8911.
https://doi.org/10.1182/blood-2022-158592
Published: 2022
Journal Articles

Immune and Epigenetic Landscape of TP53- mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Amer M. Zeidan, Jan Philipp Philipp Bewersdorf, Vanessa Hasle, Ethan G. Thompson, Daniel Lopes de Menezes, Shelonitda Rose, Isaac Boss, Brian Fox
Journal: Blood
Blood (2021) 138 (Supplement 1): 3371.
https://doi.org/10.1182/blood-2021-146329
Published: 2021
Journal Articles

Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPα Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab

Henry Chan, Christina Trout, David Mikolon, Preston Adams, Roberto Guzman, Gustavo Fenalti, Konstantinos Mavrommatis, Mahan Abbasian, Lawrence Dearth, Brian Fox, Pallavur Sivakumar, Kandasamy Hariharan
Journal: Blood
Blood (2021) 138 (Supplement 1): 2271.
https://doi.org/10.1182/blood-2021-147262
Published: 2021
Journal Articles

Multiplexed Immunofluorescence (IF) Analysis and Gene Expression Profiling of Biopsies from Patients with Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL) Treated with Lisocabtagene Maraleucel (liso-cel) in Transcend NHL 001 Reveal Patterns of Immune Infiltration Associated with Durable Response

David J. Reiss, PhD, Trevor Do, David Kuo, Vanessa E. Gray, N. Eric Olson, Chung-Wein Lee, Mary H. Young, PhD, Shradha Srinivasan, Falon D. Gray, DVM, DACVP, Brian Fox, Suzana Couto, Jason A. Dubovsky, PhD, Frank Schmitz, Kathryn Newhall
Journal: Blood
Blood (2019) 134 (Supplement_1): 202.
https://doi.org/10.1182/blood-2019-127683
Published: 2019
Journal Articles

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Carla Casulo, Armando Santoro, Kiyoshi Ando, Steven Le Gouill, Jia Ruan, MD PhD, John Radford, Luca Arcaini, Antonello Pinto, Reda Bouabdallah, Koji Izutsu, MD PhD, Simon Rule, Javier Munoz, MD, Marie-Laure Casadebaig, Brian Fox, Nils Rettby, Justine Dell'Aringa, Richard Delarue, Kathryn Newhall, Myron Czuczman, Guillaume Cartron
Journal: Blood
Blood (2019) 134 (Supplement_1): 5320.
https://doi.org/10.1182/blood-2019-124102
Published: 2019